Oregon's Regulated Psilocybin Services Model

In November 2020, Oregon voters approved Measure 109, the Psilocybin Services Act, making the state the first jurisdiction in the world to create a formal, licensed regulatory framework for the supervised administration of psilocybin. Unlike decriminalisation measures, which simply remove or reduce criminal penalties, Measure 109 established an entire system of licensed production, testing, facilitation, and service delivery — all under the oversight of the Oregon Health Authority (OHA). The model is deliberately narrow: psilocybin is not sold for home use, and it is not available without a trained facilitator. Instead, it is offered as a supervised service, consumed on-site at licensed service centres. For policy observers in South Africa and elsewhere, Oregon's framework has become a reference point for what regulated psilocybin access could look like — and for the challenges of building such a system from scratch.

The ballot measure and its mandate

Measure 109 passed with approximately 56% of the vote and instructed the OHA to develop a regulatory framework for psilocybin services within two years. The measure created the Oregon Psilocybin Advisory Board, composed of experts in medicine, ethics, public health, and Indigenous practices, to provide recommendations to the OHA. Notably, the measure did not legalise psilocybin for general recreational use, nor did it authorise medical prescription in the conventional sense. Instead, it carved out a distinct category: psilocybin services, defined as the administration, supervision, and support of psilocybin use in a licensed setting. The measure also specified that participation is limited to adults aged 21 and over, and that clients must complete a preparation session before an administration session. Oregon's approach is often described as a service model rather than a retail model — closer to a therapeutic or ceremonial framework than to a dispensary.

Licensing tiers and structure

The OHA's final rules, adopted in late 2022 and effective from January 2023, created four licence types: manufacturers, laboratories, service centres, and facilitators. Manufacturers are licensed to produce psilocybin products, but only for supply to licensed service centres — not for direct retail. Testing laboratories are licensed to analyse psilocybin products for contaminants and potency. Service centres are licensed venues where psilocybin is administered to clients under the supervision of a licensed facilitator. Facilitators are individuals licensed to prepare clients for, supervise during, and support clients after psilocybin administration sessions. The system is vertically separated: a single entity can hold multiple licences, but each carries its own requirements and obligations. This layered structure is designed to create accountability at each stage of the supply chain, from production to supervised consumption.

Facilitator training and safeguards

To become a licensed facilitator, an individual must complete an OHA-approved training programme at an approved institution. Training programmes cover topics such as psilocybin pharmacology, ethics, trauma-informed care, cultural equity, and session facilitation. Facilitators are not required to be medical professionals — the measure deliberately chose not to restrict facilitation to licensed clinicians — but they must pass an examination and meet ongoing education requirements. Safeguards built into the model include mandatory preparation sessions, where facilitators screen clients and discuss the process; mandatory on-site administration; and a post-session integration support requirement. Facilitators are also expected to screen for contraindications, such as certain psychiatric conditions or medications, although the model does not require a medical diagnosis or prescription for access. The screening process is facilitator-led rather than physician-led, which has drawn both praise — for broadening access — and criticism from those who argue that medical oversight should be stronger.

Early implementation and challenges

Oregon's psilocybin services began operating in 2023, with the first licensed service centres opening mid-year. Early implementation has highlighted several tensions. Costs remain high, with session fees reportedly running into hundreds or thousands of US dollars, raising equity concerns about who can access the services. Insurance generally does not cover psilocybin sessions, as psilocybin remains a Schedule I substance under United States federal law — a reminder that state-level reform operates within, not outside, a federal controlled-substance framework. Some Oregon counties and cities have voted to place moratoria or bans on psilocybin service centres within their borders, reflecting local variation in public support. Researchers and policymakers continue to study whether Oregon's model achieves its stated goals of reducing harm, providing safe access, and shifting psilocybin use away from unregulated markets.

Relevance to South African policy

Oregon's model is particularly relevant to South Africa, where psilocybin remains a Schedule 7 substance under the Medicines and Related Substances Act — among the most restrictive categories, with no recognised therapeutic use. The cannabis precedent in South Africa, where Constitutional Court rulings and subsequent legislative attempts have moved toward regulated access, offers a domestic parallel for how drug policy reform can proceed through a combination of litigation and regulation. Oregon's experience suggests that a regulated psilocybin framework is technically feasible but requires substantial time, resources, and institutional capacity: the OHA took over two years to draft and finalise its rules. It also illustrates the importance of public engagement, evidence-based rule-making, and clear safeguards in building public trust. For South African policymakers, Oregon provides neither a template to copy nor a model to reject, but a real-world case study of what regulated psilocybin services look like when implemented at scale — with all their promise and limitations.